|
Originally published In Press as doi:10.1074/jbc.M002195200 on June 12, 2000
J. Biol. Chem., Vol. 275, Issue 36, 27775-27783, September 8, 2000
Phosphorylation Site Analysis of Semliki Forest Virus
Nonstructural Protein 3*
Helena
Vihinen § and
Juhani
Saarinen¶
From the Program in Cellular Biotechnology and
¶ Protein Chemistry Laboratory, Institute of Biotechnology,
Viikki Biocenter, University of Helsinki,
Helsinki FIN-00014, Finland
Received for publication, March 16, 2000, and in revised form, June 7, 2000
 |
ABSTRACT |
Nonstructural protein 3 (Nsp3) is an essential
subunit of the alphavirus RNA replication complex, although its
specific function(s) has yet to be well defined. Previously, it has
been shown that Semliki Forest virus Nsp3 (482 amino acids) is a
phosphoprotein, and, in the present study, we have mapped its major
phosphorylation sites. Mass spectrometric methods utilized included
precursor ion scanning, matrix-assisted laser desorption/ionization
mass spectrometry used in conjunction with on-target alkaline
phosphatase digestions, and tandem mass spectrometry. Two-dimensional
peptide mapping was applied to separate tryptic
32P-labeled phosphopeptides of Nsp3. Radiolabeled
peptides were then subjected to Edman sequencing, and phosphoamino acid
analysis. In addition, radiolabeled Nsp3 was cleaved successively with
cyanogen bromide and trypsin, and microscale iron-chelate affinity
chromatography was used to enrich phosphopeptides. By combining these
methods, we showed that Nsp3 is phosphorylated on serine residues 320, 327, 332, 335, 356, 359, 362, and 367, and is heavily phosphorylated on
peptide Gly338-Lys415, which carries 7-12
phosphates distributed over its 13 potential phosphorylation sites.
These analytical findings were corroborated by constructing a Nsp3
derivative devoid of phosphorylation. The results represent the first
determination of phosphorylation sites of an alphavirus nonstructural
protein, but the approach can be utilized in phosphoprotein analysis in general.
 |
INTRODUCTION |
The phosphorylation and dephosphorylation of proteins play a
crucial role in the regulation of many cellular processes. In viral
systems, the phosphorylation of specific proteins modulates virus
replication and virus-host interactions (1). For example, the
phosphorylation of the P protein in several negative-strand RNA viruses
has been found to be essential for the viral transcription activity (2,
3).
Alphaviruses, such as Semliki Forest virus
(SFV),1 Sindbis virus (SIN),
and Venezuelan equine encephalitis virus, are enveloped positive-strand
RNA viruses capable of causing disease in mammals including man. The
RNA genome of SFV (total length ~11.5 kilobases) codes for two
polyproteins, nonstructural and structural. The nonstructural
polyprotein (P1234), is autoproteolytically cleaved into the four
nonstructural proteins Nsp1-Nsp4 (reviewed in Refs. 4 and 5).
Recently, studies have shown that SFV Nsp1 has nucleotide methylation
and viral mRNA capping functions (6, 7). Nsp2 was found to be the
autoprotease responsible for the cleavage of the nonstructural
polyprotein (8), an RNA helicase (9), and an RNA triphosphatase (10).
As for Nsp4, protein sequence homology with other viral proteins of
known function suggests that Nsp4 is the catalytic subunit of the SFV
RNA-dependent RNA polymerase (11). Whereas functions have
been determined for the other nonstructural proteins, the function of
Nsp3 remains poorly characterized. Studies of SIN polyprotein
processing intermediates containing Nsp3 have shown that it is
essential for the synthesis of negative-strands during the early phase
of RNA replication (12, 13). In addition, SIN Nsp3 has been reported to
putatively affect the synthesis of subgenomic mRNA encoding the
virus structural proteins (14, 15).
Amino acid sequence comparisons suggest that N-terminal regions of
alphavirus Nsp3s are highly conserved sharing significant similarity
with rubella virus, hepatitis virus E, and coronavirus sequences (16).
Furthermore, a recent genomic analysis has revealed that sequences
related to the Nsp3 N-terminal domain are widely found in bacteria,
animals, and plants (17). The conservation of this region during
evolution suggests an important and basic function for this domain,
which for the moment remains unclear. In contrast, the C-terminal
region of Nsp3 is not conserved among alphaviruses and varies both in
sequence and in length from 134 aa in Middelburg virus to 246 aa in
O'nyong-nyong virus (5). However, some similarities do exist in the
C-terminal domains of alphaviruses, e.g. all are rich in
acidic residues, as well as in serine and threonine, and devoid of any
predicted secondary structure. It appears that Nsp3 is the only
alphavirus nonstructural protein, which is modified by phosphorylation
(18, 19). Phosphoamino acid analysis of SFV Nsp3 (total of 482 aa)
showed that serine and threonine residues are phosphorylated in the
approximate ratio of 2:1 (18), but the exact positions of
phosphorylated Nsp3 residues have not been reported. The identification
of phosphorylation sites in Nsp3 is important for a number of reasons
including: determining whether Nsp3 phosphorylation sites are constant
or changed during virus evolution, mapping potential changes in
phosphorylation patterns during alphavirus infection in different
tissues, and determining potential phosphorylation sites for future
mutagenesis studies. Furthermore, because information regarding
phosphorylation sites in SFV Nsp3 represents the first systematic
mapping of such sites in alphaviruses, it would represent a model for
other related pathogenic viruses.
Detailed characterization of protein phosphorylation is hampered by the
low amount of material available for analysis, and by the fact that the
stoichiometry of protein phosphorylation is often very low,
i.e. the phosphopeptides exist as a minor fraction in a
large background of unphosphorylated peptides. Advances in ionization
methodologies (electrospray and matrix-assisted laser desorption/ionization (MALDI)) have made biological mass spectrometry effective and sensitive enough for studying posttranslational protein
modifications (20, 21). Recently, mass spectrometric methods for
phosphorylation analysis after SDS-PAGE separation have been described
(22, 23). Although mass spectrometry has become a very efficient tool
in the identification of phosphopeptides, problems still remain. For
example, when a peptide contains multiple phosphates and many potential
phosphorylation sites, the site-specific identification of
phosphorylated residues is often limited by the fact that multiply
phosphorylated peptides are likely to produce very complex
collision-induced decomposition (CID) spectra, or ionize poorly in the
positive ion mode. SFV Nsp3 is a challenging molecule for
phosphorylation studies, since it has relatively high number of
potential phosphorylation sites (39 Ser and 35 Thr residues), and the
protein is somewhat resistant to enzymatic cleavage. However, by using
the mass spectrometric methods along with two-dimensional
phosphopeptide mapping and Edman sequencing, we were able to map the
major, if not all, phosphorylation sites of Nsp3. Based on these
results, we constructed a deletion/point mutation derivative of Nsp3,
which could not be phosphorylated as judged by loss of 32P
incorporation, thus further supporting the validity of phosphorylation site analysis.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Construction--
Deletion and point mutations were made
in the NSP3 coding region, which was originally cloned into
plasmid pTSF3 under the control of the T7 promoter (24). A deletion
mutant, which had amino acids between 342 and 369 of Nsp3
removed, was made using PCR with the following primers: 1, 5'-CTCAAGCTTATGCACCCGCGCGGCCTAGTCG-3'; 2, 5'-ATCACCATGGCACCATCCTACAGAGTTAAG-3'; 3, 5'-TCGTAGTCCAAGTCAAACCCTCGTAACGACCGATC-3'; 4, 5'-TGGACTACGAGCCAATGGCTCCCATAGTAGTGACGG-3'. The PCR products were
purified and used as templates in a second round of PCR with primers 2 and 4. Serine residues 320, 327, 332, and 335 were mutated to alanine
by using a site-directed mutagenesis kit (U.S.E. kit, Amersham
Pharmacia Biotech) according to the manufacturer's instructions. A
Nsp3 mutant containing both the 343-368 deletion and the four point
mutations was designated Nsp3 26+4S 4A. All sequence alterations were verified by DNA sequencing.
Expression and Metabolic Labeling in HeLa Cells--
HeLa cell
monolayers were grown in Dulbecco's modified minimal essential medium
supplemented with 10% heat-inactivated fetal calf serum, and 100 units/ml streptomycin and penicillin. The modified vaccinia virus
Ankara was kindly provided by Dr. B. Moss (National Institutes of
Health, Bethesda, MD), and virus stocks were made as described
previously (25). HeLa cell dishes that were 80-90% confluent were
infected with virus using 20-50 plaque-forming units/cell. After a
45-min adsorption period, the cells were washed, and transfected using
Opti-MEM (Life Technologies, Inc.), the pTSF3 plasmid or its
derivatives, and Lipofectin (Life Technologies, Inc.). Transfection
mixtures of 7 µg of DNA in 12 µl of Lipofectin, and 10 µg of DNA
in 50 µl of Lipofectin were used for 60- and 100-mm plates,
respectively. After 3-4 h, the transfection mixture was replaced with
medium containing 0.2% bovine serum albumin. Cells were then incubated
for 1-3 h at 37 °C. For in vivo labeling, transfected
cells were washed twice at 2 h after transfection with Dulbecco's
medium containing 0.2% bovine serum albumin, after which
methione/cysteine-free or phosphate-free medium was added. Cells were
labeled at 3 h after transfection either with 150 µCi of
[35S]methionine/cysteine (>1000 Ci/mmol, Redivue
PRO-mix, Amersham Pharmacia Biotech) or with 300-1000 µCi of
carrier-free [32P]orthophosphate (10 mCi/ml, Amersham
Pharmacia Biotech) per plate. After 3-5 h at 37 °C, cells were
washed carefully, harvested, and lysed in 1% SDS.
Immunoprecipitation, SDS-PAGE, and Immunoblotting--
HeLa
cells were lysed in phosphate-buffered saline containing 1% SDS, 10 mM sodium fluoride (Merck), and a protease inhibitor mixture at a recommended concentration (CompleteTM; Roche
Molecular Biochemicals). After shearing the DNA by drawing the lysate
repeatedly through a 27-gauge needle, the proteins were denatured by
boiling, and Nsp3 was immunoprecipitated with anti-Nsp3 rabbit
antiserum, as described previously (18). Proteins were separated in
10% SDS-PAGE gels, and electrotransferred to nitrocellulose (Hybond-C Extra, Amersham Pharmacia Biotech) or polyvinylidene difluoride membrane (PVDF; Immobilon, Millipore) as described previously (6). For
phosphopeptide mapping analysis, samples were alkylated in 10 mM dithiothreitol, 3 mM EDTA, and 20 mM iodoacetamide for 15 min prior to separation by
SDS-PAGE. Radiolabeled proteins were detected by using an imaging
system (Fuji BAS 1500).
In-gel Digestion of Nsp3 for ESI-MS
Analysis--
Immunoprecipitated Nsp3 was resolved by 10% SDS-PAGE
and detected by Coomassie Blue staining. The Nsp3 band, corresponding to approximately 1 µg of protein (20 pmol), was excised and destained by rinsing the gel pieces twice in 0.1 M
NH4HCO3 in 50% acetonitrile (ACN) for 45 min
at 37 °C. Gel pieces were then dehydrated with 100% ACN and
vacuum-dried. Gel pieces were rehydrated in 10 µl of 0.1 M NH4HCO3, 10% ACN containing 40 ng/µl trypsin (modified trypsin, sequencing grade, Promega). The
trypsin digestion was performed overnight. The samples were desalted by
miniature reversed-phase chromatography column as described previously
(22) using POROS R2 (Perseptive Biosystems) as absorbent. The sample
was eluted with 2 µl of 0.5% ammonia in 50% methanol directly to
the nanoelectrospray needle.
Cyanogen Bromide Degradation in SDS-PAGEs--
Approximately 5 µg (100 pmol) of 32P-labeled Nsp3 was obtained from a
dried gel piece, as described above. Cleavage with cyanogen bromide
(CNBr) was performed with 5 mg/ml CNBr in 70% trifluoroacetic acid in
the dark for 18 h at room temperature. The peptides were extracted
once with 150 µl of aqueous 50% ACN for 30 min at 37 °C, and
twice with 150 µl of 5% formic acid in 50% ACN for 45 min at
37 °C. The supernatants were combined and lyophilized. To reduce the
amount of CNBr in samples before reversed-phase HPLC, samples were
dissolved in 100 µl of deionized water, and lyophilized. This
treatment was repeated three times. The peptides were dissolved in 1%
trifluoroacetic acid and applied to 37 °C reversed-phase HPLC.
Separation of CNBr Fragments by Reversed-phase
HPLC--
Peptides resulting from CNBr digestion were separated by
reversed-phase HPLC on a 1 × 20-mm C-1 column (TMS-C1, 300 Å, 5 µm; Tosoh Corp.) by elution with a linear gradient of acetonitrile (5-100% in 60 min) in 0.1% trifluoroacetic acid. Chromatography was
performed at a flow rate of 50 µl/min, and the elution was monitored
by UV absorbance at 214 nm. Fractions were taken at 1-min intervals,
and 0.3-µl aliquots were spotted on a PVDF membrane, air-dried, and
analyzed for 32P radioactivity by phosphoimaging.
Trypsin Digestion of CNBr Fragments--
After reversed phase
chromatography of CNBr-digested Nsp3, fractions containing
radioactivity were combined into three pools corresponding to their
elution time from the C-1 column. Pool 1 contained early eluting
radioactive fractions, pool 2 middle eluting fractions, and pool 3 consisted of late eluting components. Each pool was lyophilized and
dissolved in 50 µl of digestion buffer (0.1 M
NH4HCO3 in 10% ACN) containing 0.05 µg/µl
trypsin. The digestion was performed at 37 °C for 18 h, after
which fractions were lyophilized and dissolved into 10 µl of 1%
trifluoroacetic acid. Half of each trypsin-digested pool was subjected
to separation by reversed-phase HPLC on a 0.3 × 20-mm C-8 column
(Vydac C8, 300 Å, 9 µm). Peptides were eluted with a linear gradient
of ACN (5-100% in 60 min) in 0.1% trifluoroacetic acid at a flow
rate of 5 µl/min, and elution was monitored by UV absorbance at 206 nm. Fractions were collected every 2 min, and radioactive fractions were identified by phosphoimaging.
Immobilized Metal Chelate Affinity Chromatography--
To enrich
for phosphorylated peptides, tryptic peptides made from CNBr-digested
Nsp3 were applied to a miniature Fe3+ column consisting of
0.5 µl of POROS MC (Perseptive Biosystems) packed into a gel-loader
pipette tip. The column was equilibrated with 30 µl of equilibration
buffer (2:1 v/v mixture of 0.1 M ammonium acetate, pH 3.1, and acetonitrile). One microliter of tryptic/CNBr-digested peptides
from all three pools were combined, which represented 10% of the total
sample and 10 pmol of Nsp3 protein starting material, diluted 1:10 in
equilibration buffer, and passed through the column. The column was
washed with 20 µl of equilibration buffer, and washed again with 20 µl of equilibration buffer diluted 1:10 in H2O. Peptides
were eluted with 5 µl of 0.5% ammonia in 50% methanol and directly
applied to the MALDI target plate, as 1-µl fractions.
On-target Alkaline Phosphatase Treatment--
After
MALDI-time-of-flight (TOF) mass analysis of fractions from
Fe3+-chromatography, in both positive and negative ion
mode, the samples (prepared on the MALDI target plate with
2,4,6-trihydroxyacetophenone (THAP) matrix, as described below) were
dissolved in 0.5 µl of 50 mM
NH4HCO3, pH 8.9, containing 0.01 units of calf
intestinal alkaline phosphatase (CIP, New England Biolabs). Samples
were then incubated for 2 h at 37 °C in a high humidity chamber
to prevent drying. Dephosphorylation was stopped by the addition of 0.5 µl of ACN, and samples were immediately dried in vacuo to
allow for proper crystallization of the matrix.
Mass Spectrometry--
MALDI-TOF mass spectrometry was performed
on a BiflexTM time-of-flight instrument (Bruker-Franzen Analytik,
Bremen, Germany) equipped with a nitrogen laser operating at 337 nm.
The Fe3+-affinity chromatography fractions, as well as
products from the phosphatase reactions were analyzed both in the
linear negative ion delayed extraction mode, and reflector positive ion
delayed extraction mode, using THAP, 3 mg/ml in acetonitrile with 20 mM aqueous diammonium citrate, 1:1, by volume, as the
matrix. Samples were prepared as described previously (26), and all
mass spectra were externally calibrated with angiotensin II and
adrenocorticotropic hormone corticotropin-like intermediate peptide.
The Nsp3 phosphopeptides isolated by reversed phase chromatography were
analyzed in the reflector positive ion delayed extraction mode using an
-cyano-4-hydroxycinnamic acid saturated solution in 0.1%
trifluoroacetic acid and 30% acetonitrile as the matrix. Samples were
prepared by mixing 0.5 µl of eluate with 0.5 µl of -cyano-4-hydroxycinnamic acid matrix on the target plate, and dried
under a gentle stream of warm air. Mass spectra were calibrated as above.
Electrospray ionization (ESI) precursor ion scan mass spectra were
obtained using an API 365 triple quadrupole mass spectrometer (PE-Sciex, Ontario, Canada) with a nanoelectrospray source installed. Q1 scans were acquired with 0.1-Da step width and a dwell time of 1 ms,
at 1-unit resolution. Precursor ion scans were acquired with a step
width of 0.5 Da, and a dwell time of 50 ms. The resolution was set to
transmit a mass window of 4 Da, the collision gas used was nitrogen,
and the collision energy was set to 150 V.
Electrospray ionization product ion mass spectra were collected using a
Micromass Q-TOF quadrupole/time-of-flight hybrid mass spectrometer
(Micromass, Manchester, United Kingdom) with a nanoelectrospray source
installed. Product ion scans were acquired with a Q1 resolution set to
transmit a mass window of 5 Da. The doubly charged parent ions [M + 2H]2+ were selectively transmitted by the first mass
analyzer and directed into the collision cell containing argon as the
collision gas. Collision energies were adjusted for each experiment individually.
Tryptic Phosphopeptide Mapping--
32P-Labeled Nsp3
or its derivatives were immunoprecipitated, resolved by SDS-PAGE, and
blotted either onto nitrocellulose or PVDF membrane. PVDF membrane was
dried prior to detection by phosphoimaging, but the nitrocellulose
membrane was kept moist during the localization of the bands by placing
it into a plastic bag. The membrane pieces were excised and saturated
with 0.5% polyvinylpyrrolidone 360 at 37 °C for 1 h. The
membrane pieces were washed several times with 10% ACN, and the
protein was digested with trypsin in 50 mM
NH4HCO3 in 10% ACN. After overnight incubation
at 37 °C, the buffer was evaporated by several rounds of
lyophilization, and the tryptic peptide mixture was dissolved in 5 µl
of 128 mM ammonium carbonate buffer, pH 8.9, and the entire
sample was spotted onto a 20 × 20-cm cellulose thin layer
chromatography (TLC) plate. The first dimension, thin layer
electrophoresis (TLE), was performed at 1.0 kV for 24 min in the same
buffer. The plate was then air-dried overnight, after which ascending
chromatography was performed in n-butyl
alcohol:pyridine:acetic acid:water at 15:10:3:12, v/v/v/v. The plate
was air-dried, and phosphopeptides were detected by phosphoimaging.
Edman Sequencing--
Phosphopeptides localized on TLC plates
were recovered from the plate by elution with a solution of formic
acid, acetic acid, water, 25:78:897 v/v/v, pH 1.9. The 32P
content of each sample was determined by Cerenkov counting. One-tenth
of each sample volume was analyzed by phosphoamino acid analysis, and
rest of each sample was subjected to Edman degradation as described by
Blume-Jensen et al. (27). Peptides were coupled to
Sequelon-AA membranes, and Edman degradation was performed on an ABI
sequencer model 477A. Released phenylthiohydantoin amino acid
derivatives from each cycle were spotted on TLC plates, and the
radioactivity was quantified by digital imaging after the subtraction
of background.
 |
RESULTS |
Identification of Phosphopeptides in Tryptic Peptides from
Nsp3--
Since only a small amount of Nsp3 is synthesized in cells
during SFV infection, we used vaccinia-aided transfection to produce sufficient quantities of Nsp3 for phosphorylation analysis. HeLa cells
were first infected with the modified vaccinia virus Ankara, which has
been engineered to express T7 RNA polymerase (25). Infected cells were
then transfected with a plasmid encoding SFV Nsp3 under the control of
the T7 promoter. Nsp3 was isolated from cell lysates by
immunoprecipitation, liberated from the immunoprecipitation affinity
matrix by boiling in Laemmli sample buffer, and further purified by
SDS-PAGE. The Nsp3 band visualized on the gel was subjected to in-gel
digestion with trypsin. Tryptic peptides were extracted from the gel
and desalted using microscale reversed-phase chromatography. Peptide
mixtures were eluted directly into a nanospray needle and subjected to
mass analysis using a triple quadrupole instrument, which provides high
sensitivity for precursor ion scanning. The Q 1 scan displayed in Fig.
1A was acquired in the negative ion mode, and it shows a distribution of several signals, indicating good recovery of peptides. A precursor ion scan of m/z (mass/charge) 79 in the negative ion mode is displayed
in Fig. 1B, and it shows two major peaks at m/z
852 and 916, which were tentatively identified as [M 2H]2 of peptides Val308-Arg322
and Val308-Lys323, respectively (for sequence,
see Fig. 1D). Each peak appear to carry a single phosphate
moiety. Signals at m/z 568 and 610 were identified as
[M 3H]3 counterparts for the 852 and 916 species. In Fig. 1B, a series of short peaks (bump-like
signals) can be seen between m/z 600 and 1200, and are
tentatively identified as a charge series m/z [M 14H]14 to [M 8H]8 of peptide
Gly338-Lys415. This peptide appears to carry
7-12 phosphates distributed over its 13 potential phosphorylation
sites. This assignment was confirmed by double-digestion data as well
as site-specific mutation data, as shown below. In Fig. 1B
(inset), a close-up of the [M 11H]11
species is shown. Fig. 1C shows the results from an product
ion scan, using a quadrupole-time of flight instrument, done on 853.44 [M + 2H]2+ ion (Fig. 1B). Using CID analysis,
the peptide produced a clear Y-ion series, which allowed for both the
identification of the peptide as Val308-Arg322
with one phosphate moiety, and the assignment of phosphorylation at
Ser320. An expansion of region 450-650 (Fig.
1C) shows ions Y3 ( m/z 439.22), Y4 (
m/z 538.31), and Y5 ( m/z 637.33), which are
diagnostic of phosphorylation at Ser320, and would be
absent if the phosphorylation occurred either at residues
Ser317 or Thr314. Furthermore, the peptide at
917,49 [M + 2H]2+ was analyzed by CID MS, and found to be
peptide Val308-Lys323, and it also showed
Ser320 to be phosphorylated (data not shown). At this point
it was evident that the other phosphopeptides observed in the precursor
ion scan could not be further analyzed by mass spectrometry alone (see "Discussion").

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 1.
Phosphopeptide analysis of Nsp 3 after in-gel
trypsin digestion and the amino acid sequence of C-terminal part of
Nsp3. A, negative ion ESI Q1 scan of the peptide
mixture after elution from the POROS R2 microcolumn. B,
precursor ion scan of m/z 79 of the same sample showing
putative phosphopeptides; inset, close-up of m/z
790-850 showing a [M 11H]11 of a species
carrying 7-12 phosphates. C, ESI-CID MS analysis of the
853.4 [M + 2H]2+ ion. The sequence of the peptide and the
phosphorylation site could be determined from a Y-ion series.
Diagnostic ions Y3 to Y5, which allow for localization of
phosphorylation to Ser320, are marked with an
asterisk and shown in the inset.
Spectra A and B were acquired using a
triple-quadrupole instrument, and spectrum C
using a quadrupole-time of flight instrument. D, amino acid
sequence of the C-terminal part of SFV Nsp3. Cleavage sites by trypsin
(Trp) and CNBr are marked with lines.
|
|
Double Digestion of Nsp3 by CNBr and Trypsin--
As suggested by
the precursor ion scan experiment carried out on the tryptic digest of
Nsp3, peptide Gly338-Lys415 carries 7-12
phosphates, and has a calculated molecular weight between 8838 and 9238 Da. Such large peptide was not amenable to site-specific
phosphorylation analysis by mass spectrometry, so in order to reduce
the size of this peptide (which contains two methionines), 5 µg (100 pmol) of 32P-labeled Nsp3 was digested in-gel with CNBr,
and the resulting peptides were separated by reversed phase
chromatography (Fig. 2A).
Fractions were collected at 1-min intervals, and 0.3 µl of each
fraction was spotted to PVDF membrane for autoradiography (Fig.
2A). The resulting peptides were pooled into three pools according to the elution of radioactivity, and each pool was digested with trypsin. After trypsin digestion, an aliquot of each pool, corresponding to 50 pmol of Nsp3, was separated by microscale RP
chromatography, and again fractions were collected, with part of each
fraction being subjected to autoradiography. Radioactive fractions were
then analyzed by MALDI-TOF mass spectrometry in both positive and
negative ion modes in order to identify phosphopeptide candidates. From
RP chromatography done on pool 1 (Fig. 2B), a series of
peptides (1938.0, 2018.0, 2098.0, 2178.0, and 2258.0; [M H] , average mass), could be discerned, each separated by
80 Da. According to mass alone, the peptides could not be assigned
directly to Nsp3 sequence, even taking into consideration
phosphorylation, and possible modifications introduced by CNBr
digestion (e.g. acid cleavage, oxidation of tryptophans,
conversion of methione to homoserine (Hser) without chain cleavage).
Signal 1938.8 [M + H]+ (monoisotopic mass), which is the
smallest species in this series, was chosen for CID MS analysis,
because it would most likely produce the least complex CID MS spectrum
compared with other more phosphorylated peptides. A product ion scan of
969.9 [M + 2H]2+ was acquired using a
quadrupole-time-of-flight instrument, and upon CID the peptide produced
a mixed y- and b-ion series, which together identified the peptide as
Ser356-Met372. The methione at position 372 was found to be in the open homoserine form (not as in lactone form).
This molecular species did not contain phosphates, and it was found to
carry an acrylamide adduct on residue Cys363
(Cys-propionamide), which is a frequent modification introduced to
proteins during SDS-PAGE.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Double digestion of Nsp3 with CNBr and
trypsin. A, reversed-phase chromatography of an in-gel
CNBr-digested, 32P-labeled Nsp3, and radioactivity
distribution (spots above the chromatogram) in the eluate.
Regions 1, 2, and 3, which were pooled separately, are marked on the
chromatogram. B, microbore RP-HPLC separation of a tryptic
digest of pool 1, and radioactivity distribution in the eluate.
C, ESI-CID MS analysis of the 969.9 [M + 2H]2+
ion from fraction 11. The sequence of the peptide could be determined
from mixed y- and b-ion series.
|
|
Enrichment of Phosphopeptides by Fe3+-immobilized Metal
Chelate Affinity Chromatography Followed by MALDI Mass Analysis and
On-target Alkaline Phosphatase Treatment--
To facilitate the
identification of phosphopeptides, Fe3+-immobilized metal
chelate affinity chromatography was used for enrichment of
phosphopeptides before MALDI mass analysis. An aliquot of CNBr-trypsin double-digested peptide mixture was passed through a miniature Fe3+-charged POROS MC column, washed and eluted directly
onto a MALDI target plate. The eluate was dried under a stream of warm
air, dissolved into 1 µl of THAP matrix solution, and rapidly
crystallized under vacuum. The sample was analyzed both in the linear
negative-ion mode for maximum sensitivity for phosphopeptides, and
reflector positive-ion mode for maximum mass accuracy. The crystallized sample was then dissolved and dephosphorylated on the MALDI target plate. After dephosphorylation, the matrix was re-crystallized and
subjected to MALDI-TOF mass analysis. Comparison of the mass spectra
recorded in the linear negative ion mode before (Fig. 3, A and C) and
after dephosphorylation (Fig. 3, B and D)
revealed several signals attributable to putative phosphopeptides.
Signals (Fig. 3A) at m/z 1658.4, 1738.4, and
1818.9 were tentatively identified as peptide YAASTTDHSDRSLR
(Tyr324-Arg337), carrying 1, 2, and 3 phosphates, respectively. Signals at m/z 1786.2, 1866.2, and
1946.7 were tentatively identified as peptide KYAASTTDHSDRSLR
(Lys323-Arg337), carrying 1, 2, and 3 phosphates, respectively. These signals disappeared after CIP treatment
(Fig. 3B). However, no signal corresponding to fully
dephosphorylated forms of these peptides could be observed after CIP
treatment. This was possibly due to the basic nature of the peptide
after dephosphorylation and/or increased salt content of the sample
after dephosphorylation. However, a signal at 1706.0 was observed prior
and after to CIP treatment, which may be a non-phosphorylated peptide
Tyr324-Arg337 retained by the Fe3+
column, or an unrelated signal having the same m/z value.
Because of these results, assignment of the signals cannot be
conclusively made, but further analyses by the phosphopeptide mapping
and Edman sequencing confirmed phosphorylation within
Tyr324-Arg337 (see below). It should be noted
that the phosphorylation sites within this sequence could be only
determined by using Edman sequencing. Signals at m/z 2097.7, 2177.9, and 2257.9 were suggestive of a multiphosphorylated peptide,
which, however, could not be assigned directly to any peptide of Nsp3.
Based on the observations that a similar series of signals were present
in the chromatography fractions presented in Fig. 2, the peptide was
identified as Ser357-Met372 by CID MS. After
phosphatase treatment (D), these signals disappeared and two
new signals, 1937.6 and 2017.6 [M H] , appeared, the former representing the fully dephosphorylated peptide
and the latter representing a partially dephosphorylated peptide still
carrying one phosphate.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
MALDI TOF mass spectra of double digested
Nsp3 after elution from Fe3+-affinity column combined with
on-target dephosphorylation. Spectra A and
B were acquired in the linear negative ion mode with THAP as
the matrix. The sample was then dephosphorylated on the MALDI target,
and analyzed again in the linear negative ion mode (panels
B and D). Only the regions containing putative
phosphopeptides are shown. In panel A, signals
m/z 1658.4, 1738.4, and 1818.9, which were tentatively
identified as peptide Tyr324-Arg337, carrying
1, 2, and 3 phosphates, respectively, and signals m/z
1786.2, 1866.2, and 1946.7, which were tentatively identified as
peptide Lys323-Arg337, carrying 1, 2, and 3 phosphates, respectively, could be observed. On-target
dephosphorylation of the sample resulted in disappearance of these
signals (B). In panel C, signals
2097.7, 2177.9, and 2257.9 were suggestive of a multiphosphate peptide,
which, however, could not be assigned to Nsp3 sequence. After
phosphatase treatment (D), these signals disappeared and two
new signals, 1937.6 and 2017.6, appeared. This signal was found in the
liquid chromatography fractions, and identified as
Ser356-Met372 by CID MS (as shown in Fig.
2).
|
|
Phosphopeptide Mapping of Nsp3 and Its Derivatives--
To obtain
overall picture of the phosphorylation sites in Nsp3, and to confirm
the findings obtained by other methods, Nsp3 and two engineered mutants
were analyzed by phosphopeptide mapping. Nsp3 and its mutant forms were
labeled with [32P]orthophosphate, immunoprecipitated, and
then resolved by SDS-PAGE. Proteins were electrotransferred to
nitrocellulose or PVDF membrane, and membrane pieces that contained
Nsp3 were excised and subjected to tryptic digestion. Peptides
liberated by the digestion were analyzed for radioactive phosphate by
TLE/TLC mapping. This analysis revealed three major tryptic
phosphopeptides, which are displayed in Fig.
4A as spots labeled
a, b, and c. Phosphopeptides
a and b in Fig. 4A represent about
15% and 2%, respectively, of the total signal as quantified by
phosphoimaging. According to phosphoamino acid analysis, phosphopeptide
c (Fig. 4A) was the only peptide containing
phosphothreonine (about 25% of total phosphate for c),
while the other peptides, a and b in Fig.
4A, and d and e in Fig. 4B,
contained only phosphoserines (data not shown). Furthermore, the spot
representing phosphopeptide c migrated very slowly in the
second dimension, which was probably due to its relatively large size
(78 aa). Peptide spot c was reproducibly diffuse, which was
most likely caused by heterogeneous phosphorylation. When Nsp3 was
digested on PVDF membrane, phosphopeptide mapping revealed the same
peptides spots a and b, as seen when
nitrocellulose membrane was used, but peptide spot c
appeared not to have been eluted from the PVDF membrane (Fig.
4B). In contrast, PVDF membrane appeared to release three
other phosphopeptides, spots d, e, and
f, which were most likely concealed by peptide c
in Fig. 4A. Nsp3 double mutant, Thr344 Ala/Thr345 Ala showed a peptide-mapping pattern similar
to wt Nsp3, except for peptide spot c, which appeared
somewhat shifted in position (Fig. 4C). Since
Ser320 was identified to be a phosphorylation site using
CID MS (Fig. 1C), Nsp3 mutant Ser320 Ala was
also analyzed by phosphopeptide mapping in an attempt to identify the
phosphopeptide(s) that might contain this phosphorylation site. As
shown in Fig. 4D, this mutation appeared to completely lack
the phosphopeptide representing spot a, compared with wt Nsp3 analyzed in Fig. 4B. This was consistent with the
interpretation that phosphopeptide a was a tryptic peptide,
Val308-Pro321, which included the serine at
position 320.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Phosphopeptide mapping of Nsp3 and its
derivatives. 32P-Labeled Nsp3 or its derivatives were
expressed in HeLa cells by transfection or in BHK cells by infection,
analyzed by Western blot, using either nitrocellulose or PVDF membrane.
The bands corresponding to Nsp3 produced in HeLa cells on
nitrocellulose (A) or PVDF membrane (B) and Nsp3
mutants Thr344 Ala/Thr345 Ala on
nitrocellulose membrane (C) and Ser320 Ala
on PVDF membrane (D), and Nsp3 from SFV-infected BHK cells
on nitrocellulose (E) or PVDF (F) were cut from
the membranes and subjected to tryptic digestion. Eluted
phosphopeptides were analyzed by two-dimensional phosphopeptide mapping
(TLE/TLC) as described under "Experimental Procedures." Samples
were applied at the spot marked by arrows, and the
directions of TLE and TLC runs are marked on the sides of
the plates.
|
|
Previously, Peränen et al. (18) showed that Nsp3 is
phosphorylated at serines and threonines, in a ratio of approximately 2 to 1 in SFV-infected baby hamster kidney cells. In contrast, when HeLa
cells are transfected with Nsp3, the ratio between phosphorylated serines and threonines appeared to be higher (approximately 6 to 1;
data not shown). To study whether the phosphorylation sites utilized
during SFV infection of BHK cells and Nsp3 transfection of HeLa cells
were similar, phosphopeptide maps were made using these two conditions.
32P-Labeled Nsp3 derived from SFV infection was treated as
described above and analyzed by two-dimensional mapping. As can be seen in Fig. 4 (E and F), Nsp3 from infected BHK cells
showed a similar pattern of phosphopeptides compared with transfected
HeLa cells. Although this suggests that both cell types and expression
modes utilize similar Nsp3 phosphorylation sites, there are
reproducible differences in the relative amount of the phosphopeptides
(Fig. 4, E and F), which may reflect the
differences in serine to threonine phosphorylation ratios.
Edman Sequencing--
From TLC plates, phosphopeptides
a through g (Fig. 4, A and
B) were extracted for Edman sequencing. In the case of
phosphopeptide c, only a small sample was taken from the
center of the spot and used for further analysis. This precaution was
taken to avoid contamination from other phosphopeptides, which may be
masked by this diffuse spot. Edman sequencing was performed using an automated sequencer, and released amino acid derivatives were quantified by phosphoimaging. The interpretation of the results for
phosphopeptides a, b, d, and
e was unambiguous. As already concluded from point
mutational analysis, and verified by Edman sequencing, phosphopeptide
a was tryptic peptide
Val308-Arg322, and was phosphorylated at
Ser320 (Fig. 5A).
Phosphopeptide b was tripeptide
Ser335-Arg337, which was phosphorylated at
Ser335 (Fig. 5B). Phosphopeptides d
and e appeared to be the same tryptic peptide,
Tyr324-Arg334, with or without
Lys323, respectively (Fig. 5, C and
D), and both showed that Ser327 was
phosphorylated. Although the relative amount of 32P in spot
c, which was analyzed by Cerenkov counting, was similar to
amounts in spot a, analysis of sample c showed a
significant reduction in signal generated by Edman sequencing (Fig.
5C). Putatively, phosphopeptide c was tryptic
peptide Gly338-Lys415. This relatively long
peptide (78 aa) contained 13 potential phosphorylation sites (8 serines
and 5 threonines) and carried from 7 up to 12 phosphates, as evidenced
by precursor ion scanning. In addition, this peptide also had a
combined total of 15 aspartatic acid and glutamic acid residues, which
can covalently attach to Sequelon-AA membranes. Thus, Edman sequencing
of this kind of peptide is not likely to produce informative data (see
"Discussion"). Phosphopeptides f and g seen
in Fig. 4 (E and F) could be observed in all the
maps; however, their 32P content was too low for further
analyses (Fig. 4, B-D).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Edman sequencing of phosphopeptides from
peptide mapping. Phosphopeptides a-e
(panels A-E) from phosphopeptide mapping (see Fig.
4, A-D) were eluted to pH 1.9 buffer, coupled to
Sequelon-AA membranes and analyzed by successive cycles of Edman
degradation. The amount of 32P label released by each round
of sequencing was quantified by phosphoimaging after subtraction of the
background.
|
|
Generation of a Non-phosphorylated Nsp3 Mutant--
Based on mass
spectrometric, phosphopeptide mapping, and point mutational analysis of
Nsp3, phosphorylation sites were demonstrated at serines 320, 327, 332, and 335. From 7 up to 12 potential phosphorylation sites are suggested
in peptide Gly338-Lys415, which has a total of
8 serines and 5 threonines. In an effort to better illuminate the
phosphorylation sites in peptide
Gly338-Lys415, a 26-aa deletion mutant was
made that removed residues 343-368. This mutant removed 12 of the 13 potential phosphorylation sites in peptide
Gly338-Lys415, while maintaining highly
conserved residues such as Tyr324. Remaining
phosphorylation sites at serines 320, 327, 332, and 335 were then point
mutated to alanines, and the final Nsp3 mutant, Nsp3 26+4S 4A, was
expressed in HeLa cells. Nsp3 26+4S 4A or wt Nsp3 were labeled with
[35S]methionine/cysteine, immunoprecipitated, and
subjected to SDS-PAGE (Fig. 6,
lanes 1 and 2, respectively). As can
be seen in Fig. 6, the mobility of Nsp3 26+4S 4A (lane
1) appeared slightly faster than the wt Nsp3
(lane 2), and would be indicative of the 26-aa deletion. Although the mutant protein was smaller than the wt Nsp3
protein, the mutations did not appear to have any obvious effects on
expression levels as compared with wt Nsp3 protein. This may suggest
that the mutant form is as stable in vivo as wt Nsp3
protein. Fig. 6 also shows results from labeling Nsp3 26+4S 4A and
wt Nsp3 transfected HeLa cells with [32P]orthophosphate
(Fig. 6, lanes 3 and 4, respectively).
It appeared that the mutation made in Nsp3 26+4S 4A drastically
decreased any phosphorylation of the protein (lane
3) compared with wt Nsp3 protein (lane
4). Assuming that the 26-aa deletion and the four serine to
alanine substitutions did not affect the overall conformation of the
protein, it appears that most if not all other potential phosphorylation sites, like the one at Thr378, are not
phosphorylated to any appreciable amounts. Instead, complete loss of
32P incorporation to the Nsp3 26+4S 4A can be observed,
which suggests that we have succeeded in finding all phosphorylation
sites of Nsp3.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 6.
Phosphorylation of Nsp3 and internal deletion
mutant Nsp3 26+4S 4A. HeLa
cells were infected with modified vaccinia Ankara virus and transfected
by plasmid encoding Nsp3 26+4S 4A (lanes 1 and 3) or wild type Nsp3 (lanes 2 and
4). The cells were labeled with
[32P]orthophosphate or
[35S]methionine/cysteine as indicated. Cell extracts were
collected, immunoprecipitated with anti-Nsp3 antibody, and analyzed by
SDS-PAGE. The proteins were visualized by phosphoimaging. Molecular
mass markers (in kDa) are shown on the left.
|
|
 |
DISCUSSION |
In this study we have been able to identify most if not all of the
phosphorylation sites of SFV Nsp3 by using a combination of analytical
techniques. In summary, the main phosphorylation sites appear to be at
Ser320 and within peptide
Gly338-Lys415, which contains 7-12 phosphates
distributed over its 13 potential sites. Phosphorylation also appears
to occur, albeit to a lesser extent, within peptide
Lys323-Arg337, which is phosphorylated at
serines 327, 332, and 335. In the case of peptide
Val308-Arg322, the assignment of
phosphorylation at Ser320 was determined by precursor ion
scanning, MALDI, tandem mass spectrometry, and Edman sequencing.
In contrast, peptide Gly338-Lys415 was more
problematic for determining exact sites of phosphorylation. Although it
was determined by mass spectrometric method (precursor ion scanning)
that peptide Gly338-Lys415 carried from 7 up
to 12 phosphates, its relatively large size (78 aa) and extensive
phosphorylation did not make it amenable to further structural analysis
by mass spectrometric methods. Such a peptide creates problems, which
fall into two categories: 1) the peptide is too heavily phosphorylated
to be ionized in the positive ion mode, which is a prerequisite for
performing CID MS analysis; and 2) the peptide is far too large to
yield an informative fragmentation pattern. In addition, peptide
Gly338-Lys415 was impossible to effectively
analyze by Edman degradation sequencing. For Edman degradation, the
peptide of interest is covalently attached to an arylamine membrane via
its carboxyl groups (as well from carboxyl end as Asp and Glu
residues). The peptide is attached to the membrane via any carboxyl
groups by random, and every time the sequencing proceeds to a carboxyl
group containing residue, part of the peptide pool is released, which
can be interpreted as release of phosphoamino acid. Additionally, big
peptides are more likely to undergo unspecific chain fragmentation
under the Edman degradation conditions than small ones. The larger the
peptide, and the more acidic amino acids (Asp or Glu) the peptide
contains, the more problematic the peptide is for the Edman sequencing
approach. The peptide Gly338-Lys415 is both
large (approximately 8 kDa) and acidic (11 Asp and 4 Glu residues), and
the problems arising with sequencing are well demonstrated in the
sequence analysis of spot c (Fig. 4A), where the
peptide seems to leak radioactivity in almost every cycle. However,
from the mass spectrometric analysis, we know that the peptide carries
up to 12 phosphates on its 13 potential phosphorylation sites.
Furthermore, after CNBr cleavage and trypsin digestion, the C-terminal
part of the phosphorylated region, peptide
Ser356-Met372 appeared to have 0-4
phosphates. This indirectly indicates that the N-terminal 18-aa peptide
Gly338-Met355, carrying 8 potential
phosphorylation sites, probably contained at least 7 phosphates in the
case where the former peptide is not phosphorylated at all (since the
tryptic peptide Gly338-Lys415 contains 7-12
phosphates as judged by precursor ion scanning experiments). On the
basis of these data, we assume that the Ser and Thr residues in region
Thr344-Thr354 are the most heavily
phosphorylated residues in this peptide, although these data do not
give direct evidence regarding the phosphorylation of
Thr378. However, assuming that the 26-aa internal deletion
of Nsp3 26+4S 4A did not affect the accessibility of
Thr378 to kinase(s) by causing conformational changes, it
appears that in this Nsp3 derivative Thr378 is not modified
by phosphorylation (i.e. Nsp3 26+4S 4A does not incorporate [32P]orthophosphate even though
Thr378 is present in the sequence).
The peptides Lys323-Arg337 and
Tyr324-Arg337, both of which contain the same
potential phosphorylation sites (serines at 327, 332, and 335) went
unnoticed in the precursor ion scanning experiments, most likely
because their signals were too weak to overcome the signals arising
from peptide Gly338-Lys415 peptide in its
multiple charged states. The weak signal from Lys323-Arg337 and
Tyr324-Arg337 was probably due to signal
distribution over three different phosphorylation states, their sodium
adducts, and their different charge states. These peptides were only
observed with MALDI/CIP experiments, and further site-specific
information about phosphorylated residues could only be obtained by
Edman sequencing. Data from either the MALDI/CIP experiment or Edman
sequencing alone would not have been sufficient for unequivocal
identification of the phosphorylated residues in this region of Nsp3.
The tripeptide Ser335-Arg337 could not be
observed by MALDI/CIP experiment, probably due to matrix signals in the
mass region of the peptide. In addition, this peptide could not be
identified in the precursor ion scanning experiments, which is most
likely due to the hydrophilic nature of the peptide. Although peptide Ser335-Arg337 was probably lost in the
desalting step prior to the mass analysis, it was successfully analyzed
by Edman sequencing (Fig. 5B).
Even though several mass spectrometric methods for phosphorylation site
analysis of subpicomole amounts of protein have been presented (20-23,
28), the methods were not fully applicable for all of the
phosphopeptides found in this study for the reasons discussed above.
The levels of sensitivity achieved in all the techniques used here were
at the subpicomole level, as determined by standard proteins (such as
casein) used during validation steps. For mass spectrometric analysis,
roughly 10 pmol of protein was used for each experiment, which was
plenty for most of the analysis. Since several methodological
approaches had to be used to find out all phosphorylation sites in the
Nsp3 sequence, we consumed roughly 150-200 pmol of material to
complete all of the experiments presented in this study.
In summary, we can conclude that, in the case of Nsp3, several
independent methods were needed to localize phosphorylated residues,
and any of these methods used alone would have resulted in only partial
information. In addition, the use of deletion and point mutations were
a valuable tool for confirming results obtained by analytical
approaches. Furthermore, each analytical method used to analyze protein
phosphorylation has its own pitfalls. For mass spectrometric methods,
the phosphopeptides must be large or hydrophobic enough to allow for
desalting without significant losses (22). Although digested peptides
can be analyzed without desalting step by MALDI mass spectrometry (23),
small peptides (below 600 Da) are likely to be covered under the matrix
signals. Large peptides or peptides containing multiple phosphates are not likely to produce informative fragmentation patterns, which would
allow for site-specific assignment of phosphorylation over the
sequence. Edman sequencing data alone are not always unequivocal. Two
or more peptides in the protein sequence may produce similar radioactivity distribution profiles after sequencing. Two-dimensional TLE/TLC phosphopeptide mapping gives a good overview of the number of
phosphopeptides present in the protein of interest, but does not offer
much in the way of exact phosphorylation sites. The two-dimensional
peptide mapping is of great use when used in combination with the Edman
sequencing approach or/and point mutational analysis. Point mutational
approaches carry the risk of false assignments in the cases when the
point mutation causes a conformational change in the protein, which in
turn prevents the phosphorylation of the protein, even though the
mutated site would not actually be a phosphorylated site. As an
example, when threonines 344 and 345 or Ser320 in the Nsp3
were mutated to alanines, the overall phosphorylation of the protein
dropped by approximately 50%
,2 even though each of these
amino acids carry clearly less than 15% of total phosphate in the wt
Nsp3. This suggests that the phosphorylation of these sites affects the
phosphorylation of other sites, thus giving a false picture of overall
phosphorylation of Nsp3. Taken together, one should use combination of
several methods to be able to get a reliable picture of phosphorylation of the protein of interest.
From this study, it appears that most of the SFV Nsp3 phosphorylation
sites occur in its variable C-terminal region. Even Ser320,
one of the main phosphorylation sites of SFV Nsp3, is not conserved in
other alphaviruses. SIN Nsp3 is even more heavily phosphorylated on
serines and threonines than its relative SFV Nsp3. This extensive phosphorylation of SIN Nsp3 leads to the formation of several species
with different electrophoretic mobilities (19). Although SIN Nsp3
phosphorylation has not been investigated as extensively as SFV Nsp3
has been in this report, deletions made in the non-conserved C-terminal
region of SIN Nsp3 appeared to significantly reduce its phosphorylation
(29). In the SIN Nsp3 non-conserved C-terminal domain, there are two
separate Ser/Thr-rich areas, which could be highly phosphorylated,
causing the electrophoretically distinguishable forms observed.
Furthermore, one of the kinases involved in the phosphorylation of SIN
Nsp3 has been suggested to be casein kinase II (19). This could be the
same kinase that is involved in the phosphorylation of SFV Nsp3
residues Ser-327, Ser-335, and all of the potential Ser/Thr residues in
region Thr344-Ser367, as suggested by aa
sequences around these sites. The consensus sequence for casein kinase
II is Asp, Glu, or phosphorylated serine at the position one to three
amino acids toward the C-terminal side of to the phosphorylation
acceptor serine or threonine (30). However, phosphorylation sites at
Ser320 and Ser335 do not appear to be
associated with the casein kinase II consensus sequence. Instead, they
appear to be potential sites for protein kinase C, as well as
Ser332, since they all have the consensus sequence of
Ser/Thr-X-Arg/Lys (30). Furthermore, both casein kinase II
and protein kinase C have been reported to phosphorylate viral
nonstructural proteins among negative-strand RNA viruses (2,
31-34).
The primary objective of this study was to determine the major sites of
Nsp3 phosphorylation at first the peptide level, and if possible at the
amino acid level. To reach our goal, we combined a number of analytical
methods to generate determinate results regarding most if not all
phosphorylation sites in Nsp3. Deletion and point mutations of the
phosphorylated residues resulted in non-phosphorylated derivatives of
Nsp3 incapable of incorporating [32P]orthophosphate (Fig.
6). These results will allow us to alter the native phosphorylation
patterns of Nsp3 in the context of SFV for the ultimate goal of testing
effects of phosphorylation on SFV replication and pathogenesis.
 |
ACKNOWLEDGEMENTS |
We are grateful to Dr. Ulf Hellman and
Christer Wernstedt from Ludvig Institute of Cancer Research for
performing the Edman sequencing analysis. We also thank Dr. Nisse
Kalkkinen for valuable discussions over methodological aspects
throughout this study, as well as Dr. Jari Helin, Dr. Tero Ahola, and
Dr. Kristiina Mäkinen for their critical review of this manuscript.
 |
FOOTNOTES |
*
This work was supported by Academy of Finland Grant
8397, the Technology Development Center, and the Helsinki
University Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Inst. of Biotechnology,
P.O. Box 56, Viikinkaari 9, University of Helsinki, Helsinki FIN-00014, Finland. Tel.: 358-9-19159650; Fax: 358-9-19159560; E-mail: helena.vihinen@helsinki.fi.
Published, JBC Papers in Press, June 12, 2000, DOI 10.1074/jbc.M002195200
2
H. Vihinen, T. Ahola, M. Tuittila, A. Merits,
and L. Kääriäinen, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
SFV, Semliki Forest
virus;
SIN, Sindbis virus;
Nsp, nonstructural protein;
CID, collision-induced dissociation;
PVDF, polyvinylidene difluoride;
ESI, electrospray ionization;
MS, mass spectrometry;
ACN, acetonitrile;
CNBr, cyanogen bromide;
THAP, 2,4,6-trihydroxyaceptophenone;
CIP, calf
intestinal alkaline phosphatase;
MALDI, matrix-assisted laser
desorption/ionization;
TOF, time-of-flight;
TLC, thin layer
chromotography;
TLE, thin layer electrophoresis;
wt, wild type;
aa, amino acid(s);
PAGE, polyacrylamide gel electrophoresis;
PCR, polymerase chain reaction;
RP, reverse phase;
HPLC, high performance
liquid chromatography;
BHK, baby hamster kidney.
 |
REFERENCES |
| 1.
|
Leader, D. P,
and Katan, M.
(1988)
J. Gen. Virol.
69,
1441-1464
|
| 2.
|
Barik, S.,
and Banerjee, A. K.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6570-6574
|
| 3.
|
Chattopadhyay, D.,
and Banerjee, A. K.
(1987)
Cell
49,
407-414
|
| 4.
|
Kääriäinen, L.,
Takkinen, K.,
Keränen, S.,
and Söderlund, H.
(1987)
J. Cell Sci. Suppl.
7,
231-250
|
| 5.
|
Strauss, J. H.,
and Strauss, E. G.
(1994)
Microbiol. Rev.
58,
491-562
|
| 6.
|
Laakkonen, P.,
Hyvönen, M.,
Peränen, J.,
and Kääriäinen, L.
(1994)
J. Virol.
68,
7418-7425
|
| 7.
|
Ahola, T.,
and Kääriäinen, L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
507-511
|
| 8.
|
Hardy, W. R.,
and Strauss, J. H.
(1989)
J. Virol.
63,
4653-4664
|
| 9.
|
Gomez de Cedrón, M.,
Ehsani, N.,
Mikkola, M.,
Garcia, J.,
and Kääriäinen, L.
(1999)
FEBS Lett.
48,
19-22
|
| 10.
|
Vasiljeva, L.,
Merits, A.,
Auvinen, P.,
and Kääriäinen, L.
(2000)
J. Biol. Chem.
275,
17281-17287
|
| 11.
|
Barton, D. J.,
Sawicki, S. G.,
and Sawicki, D. L.
(1988)
J. Virol.
62,
3597-3602
|
| 12.
|
Lemm, J. A.,
Rümenapf, T.,
Strauss, E. G.,
Strauss, J. H.,
and Rice, C. M.
(1994)
EMBO J.
13,
2925-2934
|
| 13.
|
Shirako, Y.,
and Strauss, J. H.
(1994)
J. Virol.
68,
1874-1885
|
| 14.
|
Wang, Y.-F.,
Sawicki, S. G.,
and Sawicki, D. L.
(1994)
J. Virol.
68,
6466-6475
|
| 15.
|
LaStarza, M. W.,
Lemm, J. A.,
and Rice, C. M.
(1994)
J. Virol.
68,
5781-5791
|
| 16.
|
Koonin, E. V.,
and Dolja, V. V.
(1993)
Crit. Rev. Biochem. Mol. Biol.
28,
375-430
|
| 17.
|
Pehrson, J.,
and Fuji, R.
(1998)
Nucleic Acids Res.
26,
2837-2842
|
| 18.
|
Peränen, J.,
Takkinen, K.,
Kalkkinen, N.,
and Kääriäinen, L.
(1988)
J. Gen. Virol.
69,
2165-2178
|
| 19.
|
Li, G.,
La Starza, M. W.,
Hardy, W. R.,
Strauss, J. H.,
and Rice, C. M.
(1990)
Virology
179,
416-427
|
| 20.
|
Annan, R. S.,
and Carr, S. A.
(1997)
J. Protein Chem.
16,
391-402
|
| 21.
|
Wilm, M.,
Neubauer, G.,
and Mann, M.
(1996)
Anal. Chem.
68,
527-533
|
| 22.
|
Neubauer, G.,
and Mann, M.
(1999)
Anal. Chem.
71,
235-242
|
| 23.
|
Zhang, X.,
Herring, C. J.,
Romano, P. R.,
Szczepanowska, J.,
Brzeska, H.,
Hinnebusch, A. G.,
and Qin, J.
(1998)
Anal. Chem.
70,
2050-2059
|
| 24.
|
Peränen, J.
(1991)
J. Gen. Virol.
72,
195-199
|
| 25.
|
Wyatt, L. S.,
Moss, B.,
and Rozenblatt, S.
(1995)
Virology
210,
202-205
|
| 26.
|
Nyman, T. A.,
Kalkkinen, N.,
Tolo, H.,
and Helin, J.
(1998)
Eur. J. Biochem.
15,
485-493
|
| 27.
|
Blume-Jensen, P.,
Wernstedt, C.,
Heldin, C.-H.,
and Rönnstrand, L.
(1995)
J. Biol. Chem.
270,
14192-14200
|
| 28.
|
Carr, S. A.,
Huddleston, M. J.,
and Annan, R. S.
(1996)
Anal. Biochem.
239,
180-192
|
| 29.
|
LaStarza, M. W.,
Grakoui, A.,
and Rice, C. M.
(1994)
Virology
202,
224-232
|
| 30.
|
Kennelly, P., J.,
and Krebs, E. G.
(1991)
J. Biol. Chem.
266,
15555-15558
|
| 31.
|
Huntley, C. C.,
De, B. P.,
and Banerjee, A. K.
(1997)
J. Biol. Chem.
272,
16578-16584
|
| 32.
|
Gupta, A. K.,
Blondel, D.,
Choudhary, S.,
and Banerjee, A. K.
(2000)
J. Virol.
74,
91-98
|
| 33.
|
Das, T.,
Schuster, A.,
Schneider-Schaulies, S.,
and Banerjee, A. K.
(1995)
Virology
211,
218-226
|
| 34.
|
Liu, Z.,
Huntley, C. C.,
De, B. P.,
Das, T.,
Banerjee, A. K.,
and Oglesbee, M. J.
(1997)
Virology
232,
198-206
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Malet, B. Coutard, S. Jamal, H. Dutartre, N. Papageorgiou, M. Neuvonen, T. Ahola, N. Forrester, E. A. Gould, D. Lafitte, et al.
The Crystal Structures of Chikungunya and Venezuelan Equine Encephalitis Virus nsP3 Macro Domains Define a Conserved Adenosine Binding Pocket
J. Virol.,
July 1, 2009;
83(13):
6534 - 6545.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Balistreri, J. Caldentey, L. Kaariainen, and T. Ahola
Enzymatic Defects of the nsP2 Proteins of Semliki Forest Virus Temperature-Sensitive Mutants
J. Virol.,
March 15, 2007;
81(6):
2849 - 2860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Galbraith, B. J. Sheahan, and G. J. Atkins
Deletions in the hypervariable domain of the nsP3 gene attenuate Semliki Forest virus virulence.
J. Gen. Virol.,
April 1, 2006;
87(Pt 4):
937 - 947.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. De, C. Fata-Hartley, S. G. Sawicki, and D. L. Sawicki
Functional Analysis of nsP3 Phosphoprotein Mutants of Sindbis Virus
J. Virol.,
December 15, 2003;
77(24):
13106 - 13116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Wilson, J. Lu, K. Sutphen, Y. Sun, Y. Huynh, and G. Brewer
Regulation of A + U-rich Element-directed mRNA Turnover Involving Reversible Phosphorylation of AUF1
J. Biol. Chem.,
August 29, 2003;
278(35):
33029 - 33038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tuittila and A. E. Hinkkanen
Amino acid mutations in the replicase protein nsP3 of Semliki Forest virus cumulatively affect neurovirulence
J. Gen. Virol.,
June 1, 2003;
84(6):
1525 - 1533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Salonen, L. Vasiljeva, A. Merits, J. Magden, E. Jokitalo, and L. Kaariainen
Properly Folded Nonstructural Polyprotein Directs the Semliki Forest Virus Replication Complex to the Endosomal Compartment
J. Virol.,
February 1, 2003;
77(3):
1691 - 1702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Steen, A. Pandey, J. S. Andersen, and M. Mann
Analysis of Tyrosine Phosphorylation Sites in Signaling Molecules by a Phosphotyrosine-Specific Immonium Ion Scanning Method
Sci. Signal.,
October 15, 2002;
2002(154):
pl16 - pl16.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Kujala, A. Ikäheimonen, N. Ehsani, H. Vihinen, P. Auvinen, and L. Kääriäinen
Biogenesis of the Semliki Forest Virus RNA Replication Complex
J. Virol.,
April 15, 2001;
75(8):
3873 - 3884.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H. Vihinen, T. Ahola, M. Tuittila, A. Merits, and L. Kaariainen
Elimination of Phosphorylation Sites of Semliki Forest Virus Replicase Protein nsP3
J. Biol. Chem.,
February 16, 2001;
276(8):
5745 - 5752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. I. Ivanov, P. Puustinen, A. Merits, M. Saarma, and K. Makinen
Phosphorylation Down-regulates the RNA Binding Function of the Coat Protein of Potato Virus A
J. Biol. Chem.,
April 20, 2001;
276(17):
13530 - 13540.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|